Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Yoshitaro Shindo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7419-5638; OpenAlex author ID A5016814013. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 24

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. Co-author DOI 10.1016/j.suronc.2025.102333↗
  3. Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC. Co-author DOI 10.21873/anticanres.18061↗
  4. Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). Co-author DOI 10.1002/cam4.70647↗
  5. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1111/cas.70087↗
  6. Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). Co-author DOI 10.1097/mpa.0000000000002323↗
  7. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers16142522↗
  8. [A Case of Pancreatic Cancer with Concomitant Pancreatic Metastasis of Renal Cell Carcinoma]. Co-author PMID 39948974↗
  9. The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers. First author DOI 10.1080/14737159.2023.2281482↗
  10. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study. Co-author DOI 10.21873/invivo.13380↗
  11. Hepatic artery resection and reconstruction using the right gastroepiploic artery during pancreaticoduodenectomy in advanced pancreatic cancer. Co-author DOI 10.1007/s00423-021-02120-0↗
  12. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Co-author DOI 10.1097/mpa.0000000000001772↗
  13. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Co-author DOI 10.3892/ol.2020.12291↗
  14. [Five Cases of Ten-Year Survival after Surgical Treatment of Pancreatic Cancer in Yamaguchi Prefecture]. Co-author PMID 32156955↗
  15. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Co-author DOI 10.1080/14737140.2018.1531707↗
  16. Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. Co-author DOI 10.1097/mcg.0000000000000551↗
  17. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Co-author DOI 10.1097/mpa.0000000000000880↗
  18. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  19. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  20. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Co-author DOI 10.1111/cas.13061↗
  21. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. Co-author PMID 28133195↗
  22. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000012↗
  23. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1186/1479-5876-12-175↗
  24. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Co-author DOI 10.3892/ijo.2014.2603↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroto Matsui Matsui · 21 shared papers, 2014–2026 · strength 2.62
  2. Hiroaki Nagano · 17 shared papers, 2016–2026 · strength 2.30
  3. Masao Nakajima · 10 shared papers, 2017–2026 · strength 1.87
  4. Tatsuya Ioka · 9 shared papers, 2021–2026 · strength 1.79
  5. Ryouichi Tsunedomi · 9 shared papers, 2014–2026 · strength 1.48
  6. Nobuaki Suzuki · 12 shared papers, 2014–2023 · strength 0.90
  7. Hidenori Takahashi · 4 shared papers, 2024–2026 · strength 0.89
  8. Yusaku Watanabe · 5 shared papers, 2014–2026 · strength 0.72
  9. Satoshi Matsukuma · 6 shared papers, 2016–2021 · strength 0.50
  10. Hiroaki Nagano · 3 shared papers, 2017–2024 · strength 0.48
  11. Tomio Ueno · 9 shared papers, 2014–2019 · strength 0.46
  12. Kimikazu Hamano · 3 shared papers, 2019–2025 · strength 0.45
  13. Taro Takami · 2 shared papers, 2024–2025 · strength 0.37
  14. Hidekazu Tanaka · 2 shared papers, 2024–2025 · strength 0.37
  15. Masaaki Oka · 7 shared papers, 2014–2017 · strength 0.31
  16. Yasuhiro Fujiwara · 3 shared papers, 2019–2021 · strength 0.30
  17. Mari Nabeya · 1 shared paper, 2026 · strength 0.26
  18. Katsuyoshi Ito · 2 shared papers, 2019–2024 · strength 0.25
  19. Hirofumi Akita · 1 shared paper, 2025 · strength 0.25
  20. Gen Kanesada · 1 shared paper, 2025 · strength 0.25
  21. Akira Yakabe · 1 shared paper, 2024 · strength 0.20
  22. Hideki Motobayashi · 1 shared paper, 2026 · strength 0.18
  23. Joe Matsumoto · 1 shared paper, 2026 · strength 0.18
  24. Yosuke Inoue · 1 shared paper, 2026 · strength 0.18
  25. Masaaki Murakawa · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.